XML 48 R52.htm IDEA: XBRL DOCUMENT v2.4.0.6
Collaborative Arrangements (Details) (USD $)
 3 Months Ended 12 Months Ended 1 Months Ended 3 Months Ended 12 Months Ended 3 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 6 Months Ended 12 Months Ended
Dec. 31, 2011
Sep. 30, 2011
Jun. 30, 2011
Mar. 31, 2011
Dec. 31, 2010
Sep. 30, 2010
Jun. 30, 2010
Mar. 31, 2010
Dec. 31, 2011
Dec. 31, 2010
Dec. 31, 2009
Sep. 30, 2009
Janssen Pharmaceutica, N.V.
transactions
Jul. 31, 2006
Janssen Pharmaceutica, N.V.
Jun. 30, 2006
Janssen Pharmaceutica, N.V.
Y
Sep. 30, 2011
Janssen Pharmaceutica, N.V.
Mar. 31, 2011
Janssen Pharmaceutica, N.V.
Mar. 31, 2010
Janssen Pharmaceutica, N.V.
Sep. 30, 2009
Janssen Pharmaceutica, N.V.
Dec. 31, 2011
Janssen Pharmaceutica, N.V.
Dec. 31, 2010
Janssen Pharmaceutica, N.V.
Dec. 31, 2009
Janssen Pharmaceutica, N.V.
Dec. 31, 2007
Janssen Pharmaceutica, N.V.
Sep. 30, 2009
Mitsubishi Tanabe Pharma Corporation
D
Dec. 31, 2011
Mitsubishi Tanabe Pharma Corporation
Dec. 31, 2010
Mitsubishi Tanabe Pharma Corporation
Dec. 31, 2009
Mitsubishi Tanabe Pharma Corporation
Apr. 30, 2011
Cystic Fibrosis Foundation Therapeutics Incorporated
Y
Dec. 31, 2011
Cystic Fibrosis Foundation Therapeutics Incorporated
payments
Dec. 31, 2006
Cystic Fibrosis Foundation Therapeutics Incorporated
Jun. 30, 2011
Alios BioPharma, Inc
analogues
Y
D
Dec. 31, 2011
Alios BioPharma, Inc
Dec. 31, 2011
Alios BioPharma, Inc
Sep. 30, 2011
Alios BioPharma, Inc
lines
Jun. 13, 2011
Alios BioPharma, Inc
Schedule of Collaborative Arrangements                                                                    
Drug development costs to be paid by collaborator (as a percent)                           50.00%         50.00%                              
Tiered royalty average range, as a percentage of net sales in the Janssen territories                           mid-20% range                                        
Up-front license payment                         $ 165,000,000                                          
Decrease in revenue recognition per quarter due to change in estimate regarding period of performance under Janssen collaboration agreement                                 1,400,000 1,100,000       2,600,000                        
Deferred revenue related to up-front license payment                                     55,900,000         12,700,000                    
Total contingent milestone payments earned                                     350,000,000                              
Milestone payment earned pursuant to the collaborative agreement                             200,000,000 50,000,000     250,000,000                              
Number of financial transactions entered into related to milestones (in transactions)                       2                                            
Notice period required to terminate without cause after receipt of marketing approval (in years)                           1                                        
License fee paid upon amendment of agreement                                             105,000,000                      
Notice period required to terminate without cause (in days)                                             60                      
Collaborative revenues recognized                                                                    
Amortized portion of up-front payment                                     12,428,000 12,428,000 20,196,000     38,232,000 38,232,000 16,027,000                
Milestone revenues                                     250,000,000         68,515,000               35,000,000    
Net reimbursement (payment) for telaprevir development costs                                     (8,418,000) 9,245,000 27,711,000         1,265,000                
Reimbursement for manufacturing services                                     20,383,000 9,077,000 6,733,000     14,928,000 43,636,000 1,419,000                
Total collaborative revenues attributable to the collaboration 81,176,000 231,066,000 29,879,000 67,601,000 57,122,000 15,622,000 24,360,000 16,022,000 409,722,000 113,126,000 73,569,000               274,393,000 30,750,000 54,640,000     121,675,000 81,868,000 18,711,000   13,700,000            
Royalty revenues from sale of INCIVO 25,405,000 8,539,000 10,010,000 6,061,000 8,402,000 8,173,000 7,262,000 6,407,000 50,015,000 30,244,000 28,320,000               20,300,000                              
Collaborative funding                                                     75,000,000              
Number of years over which funding will be made (in years)                                                     5              
Milestone payment received                                               65,000,000         1,500,000          
Collaborative revenues 81,176,000 231,066,000 29,879,000 67,601,000 57,122,000 15,622,000 24,360,000 16,022,000 409,722,000 113,126,000 73,569,000               274,393,000 30,750,000 54,640,000     121,675,000 81,868,000 18,711,000   13,700,000            
Number of commercial milestone payments for achievement of certain sales levels for potentiator compound such as VX-770 (in payments)                                                       2            
Number of commercial milestone payments for achievement of certain sales levels for corrector compound such as VX-809 or VX-661 (in payments)                                                       2            
Number of nucleotide analogues discovered by acquiree (in analogues)                                                           2        
Research and development milestone payments, maximum                                                           715,000,000        
Research and development milestone payments,earned 186,438,000 189,052,000 173,604,000 158,612,000 168,888,000 170,434,000 155,082,000 143,012,000 707,706,000 637,416,000 550,274,000                                              
Commercial milestone payments, maximum                                                           750,000,000        
Notice period for termination of contract due to technical failure (in days)                                                           30        
Notice period for termination of contract after completion of clinical trials (in days)                                                           60        
Latest expiration period for royalty obligation after first commercial sale in country unless contract is terminated earlier (in years)                                                           10        
Discount rate for contingent milestones and royalty payments for development milestones, low end of range (as a percent)                                                                   3.60%
Discount rate for contingent milestones and royalty payments for development milestones, high end of range (as a percent)                                                                   6.50%
Discount rate for contingent milestones and royalty payments for commercial milestones and royalties (as a percent)                                                                   9.40%
Up-front payment                                                             60,000,000 60,000,000   60,000,000
Fair value of contingent milestone and royalty payments                                                             (70,000,000) (70,000,000)   197,720,000
Discount rate for intangible assets acquired (as a percent)                                                                   9.50%
Intangible assets                                                                   250,600,000
Goodwill                                                                   4,890,000
Deferred tax liability 243,707,000 [1]       160,278,000       243,707,000 [1] 160,278,000                                         116,121,000 116,121,000   90,935,000
Net other assets                                                                   2,230,000
Net assets                                                                   166,785,000
Noncontrolling Interest (Alios)                                                                    
Number of lines on balance sheet where noncontrolling interest is reported                                                                 2  
Milestone revenues                                     250,000,000         68,515,000               35,000,000    
Income (loss) before provision for income taxes                                                             (9,536,000)      
Provision for income taxes 22,660,000 (27,842,000) 24,448,000           19,266,000                                           (48,809,000)      
Change in fair value of contingent milestone and royalty payments                                                             69,950,000      
Net income (loss) attributable to noncontrolling interest (Alios) 29,512,000 7,342,000 (25,249,000)           11,605,000                                           11,605,000      
Restricted cash and cash equivalents (Alios) 51,878,000 [1] 0             51,878,000 [1]                                           51,878,000 51,878,000   4,575,000
Accounts receivable, net 183,135,000 [1]       12,529,000       183,135,000 [1] 12,529,000                                         0 0    
Prepaid expenses and other current assets 14,889,000 [1]       13,099,000       14,889,000 [1] 13,099,000                                         2,299,000 2,299,000   69,000
Property and equipment, net 133,176,000 [1]       72,333,000       133,176,000 [1] 72,333,000                                         1,925,000 1,925,000   885,000
Intangible assets 663,500,000 [1]       518,700,000       663,500,000 [1] 518,700,000                                         250,600,000 250,600,000   250,600,000
Goodwill 30,992,000 [1]       26,102,000       30,992,000 [1] 26,102,000                                         4,890,000 4,890,000   4,890,000
Other assets 11,268,000 [1]       17,182,000       11,268,000 [1] 17,182,000                                         133,000 133,000   76,000
Accounts payable 74,642,000 [1]       35,851,000       74,642,000 [1] 35,851,000                                         4,132,000 4,132,000   1,189,000
Accrued expenses and other current liabilities 252,299,000 [1]       134,414,000       252,299,000 [1] 134,414,000                                         4,291,000 4,291,000   1,504,000
Income taxes payable (Alios) 12,075,000 [1]               12,075,000 [1]                                           12,075,000 12,075,000    
Deferred tax liability 243,707,000 [1]       160,278,000       243,707,000 [1] 160,278,000                                         116,121,000 116,121,000   90,935,000
Other liabilities 7,287,000 [1]       2,265,000       7,287,000 [1] 2,265,000                                         1,030,000 1,030,000   682,000
Redeemable noncontrolling interest (Alios) 37,036,000 [1]               37,036,000 [1]                                           37,036,000 37,036,000   36,299,000
Noncontrolling interest (Alios) $ 141,633,000 [1]               $ 141,633,000 [1]                                           $ 141,633,000 $ 141,633,000   $ 130,486,000
[1] Amounts include the assets and liabilities of Vertex's variable interest entity ("VIE"), Alios BioPharma, Inc. ("Alios"). Vertex's interests and obligations with respect to the VIE's assets and liabilities are limited to those accorded to Vertex in its agreement with Alios. See Note B , "Collaborative Arrangements," to these consolidated financial statements for amounts.